Royce & Associates LP Has $32.17 Million Stock Holdings in Mesa Laboratories, Inc. (NASDAQ:MLAB)

Royce & Associates LP lowered its holdings in shares of Mesa Laboratories, Inc. (NASDAQ:MLAB - Free Report) by 5.6% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 271,118 shares of the medical instruments supplier's stock after selling 16,089 shares during the quarter. Royce & Associates LP owned 4.99% of Mesa Laboratories worth $32,171,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Mesa Laboratories by 3.5% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,925 shares of the medical instruments supplier's stock worth $386,000 after purchasing an additional 98 shares during the period. Alliancebernstein L.P. raised its position in shares of Mesa Laboratories by 2.6% during the fourth quarter. Alliancebernstein L.P. now owns 5,584 shares of the medical instruments supplier's stock worth $736,000 after purchasing an additional 141 shares during the period. SG Americas Securities LLC raised its position in Mesa Laboratories by 18.7% in the 1st quarter. SG Americas Securities LLC now owns 2,461 shares of the medical instruments supplier's stock valued at $292,000 after buying an additional 388 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in Mesa Laboratories by 12.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,469 shares of the medical instruments supplier's stock valued at $458,000 after buying an additional 390 shares during the last quarter. Finally, XTX Topco Ltd raised its position in Mesa Laboratories by 13.3% in the 4th quarter. XTX Topco Ltd now owns 3,382 shares of the medical instruments supplier's stock valued at $446,000 after buying an additional 398 shares during the last quarter. Institutional investors and hedge funds own 90.60% of the company's stock.

Analyst Ratings Changes

MLAB has been the topic of a number of recent research reports. Wall Street Zen lowered Mesa Laboratories from a "strong-buy" rating to a "buy" rating in a research report on Friday, May 30th. Wells Fargo & Company lowered their price target on Mesa Laboratories from $120.00 to $100.00 and set an "underweight" rating on the stock in a research report on Friday, May 30th.

Mesa Laboratories Stock Performance

Shares of NASDAQ MLAB traded up $1.64 during midday trading on Monday, hitting $77.26. 82,539 shares of the company's stock were exchanged, compared to its average volume of 80,895. The company has a quick ratio of 0.47, a current ratio of 0.63 and a debt-to-equity ratio of 0.48. Mesa Laboratories, Inc. has a 12 month low of $67.95 and a 12 month high of $155.12. The company's 50 day moving average price is $95.40 and its 200 day moving average price is $116.90. The firm has a market capitalization of $425.08 million, a PE ratio of -208.81 and a beta of 0.86.

Mesa Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, September 15th. Investors of record on Friday, August 29th will be paid a $0.16 dividend. The ex-dividend date of this dividend is Friday, August 29th. This represents a $0.64 annualized dividend and a yield of 0.83%. Mesa Laboratories's dividend payout ratio (DPR) is presently -172.97%.

Insider Activity at Mesa Laboratories

In related news, CFO John Sakys sold 642 shares of the business's stock in a transaction on Monday, June 16th. The stock was sold at an average price of $97.12, for a total value of $62,351.04. Following the completion of the sale, the chief financial officer directly owned 12,865 shares in the company, valued at $1,249,448.80. The trade was a 4.75% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Brian David Archbold sold 472 shares of the business's stock in a transaction on Monday, June 16th. The shares were sold at an average price of $97.12, for a total value of $45,840.64. Following the completion of the sale, the senior vice president owned 558 shares of the company's stock, valued at $54,192.96. This trade represents a 45.83% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 3,053 shares of company stock worth $296,507 in the last ninety days. 4.40% of the stock is owned by company insiders.

About Mesa Laboratories

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.